|1.||Glover, Thomas W: 4 articles (12/2013 - 10/2004)|
|2.||Arlt, Martin F: 3 articles (10/2011 - 10/2004)|
|3.||Dicker, David T: 3 articles (10/2007 - 01/2002)|
|4.||El-Deiry, Wafik S: 3 articles (10/2007 - 01/2002)|
|5.||Pommier, Yves: 3 articles (09/2007 - 05/2003)|
|6.||Tunca, B: 3 articles (01/2002 - 05/2000)|
|7.||Egeli, U: 3 articles (01/2002 - 05/2000)|
|8.||Lin, Fu-Pang: 2 articles (01/2015 - 01/2008)|
|9.||Kerem, Batsheva: 2 articles (01/2015 - 05/2007)|
|10.||Chang, Chi-Yao: 2 articles (01/2015 - 01/2008)|
|1.||Chromosome Aberrations (Chromosome Abnormalities)
01/01/2012 - "In particular, for the first time, we surprisingly found a dramatic increase in the proportion of pericentromeric chromosomal aberrations relative to total aberrations in HPV16 E6E7-expressing cells 72 h after release from aphidicolin (APH)-induced replication stress, with pericentromeric chromosomal aberrations becoming the predominant type of structural aberrations (~70% of total aberrations). "
11/29/1999 - "The expression of aphidicolin (apc)-produced common fragile sites and chromosome aberrations observed 24 h after apc treatment was studied in a normal individual. "
11/29/1999 - "Chromosome aberrations induced by aphidicolin."
04/01/1998 - "Under these conditions, a very high number of chromosome aberrations were obtained: R-bands carrying FS were specifically involved in breakage and, in particular, the common FS (cFS) bands already expressed in aphidicolin-treated cultures were the most affected. "
01/01/1990 - "The level of chromosomal aberrations was compared with that found in aphidicolin-treated cultures from 12 normal subjects of the same age. "
01/01/1992 - "The drug was cleared from plasma very rapidly (clearance, 41.6 ml min-1 kg-1), showing a half-life of 15 min. Aphidicolin concentrations in the tumor were approximately 50% of those found in plasma at steady state. "
01/01/2015 - "Oncogene-induced FSs colocalize with cancer breakpoints and large genes, similar to aphidicolin-induced FSs. "
01/08/2008 - "Here, we have produced FHIT/FRA3B deletions closely resembling those in tumors by exposing human-mouse chromosome 3 somatic hybrid cells to aphidicolin-mediated replication stress. "
01/01/2005 - "This shows that liposomal encapsulation is a promising strategy for the improvement of systemic anti-cancer activity of aphidicolin."
01/01/2005 - "Aphidicolin, a tetracyclic diterpene antibiotic produced by Cephalosporium aphidicola, is under investigation as anti-cancer drug. "
01/01/2005 - "To improve the pharmacokinetics, a liposomal preparation of aphidicolin was developed and tested in neuroblastoma-bearing (UKF-NB-3) mice. "
06/01/2001 - "Treatment of drug-resistant human neuroblastoma cells with cyclodextrin inclusion complexes of aphidicolin."
07/01/2000 - "Aphidicolin (APH), a tetracyclic diterpene antibiotic produced by Cephalosporium aphidicola, has a specific toxicity for neuroblastoma cells. "
01/01/1997 - "Aphidicolin is a tetracyclic diterpene antibiotic which kills human neuroblastoma cells (NB) in vitro while it has no significant effect on the viability of different human cell types including normal embryonal cells. "
09/01/1993 - "Further evidence that neuroblastoma cells were arrested before the G1-S interface was provided when cells inhibited by DFO and released into aphidicolin exhibit arrest at the G1-S interface, whereas release from aphidicolin into DFO resulted in entry into S phase. "
|4.||Breast Neoplasms (Breast Cancer)
06/01/1993 - "The expression of fragile sites induced by aphidicolin (APC) was evaluated on metaphase chromosomes obtained from the peripheral blood lymphocytes of 26 women with breast cancer and 15 sex- and age-matched normal controls. "
06/01/1993 - "Expression of aphidicolin-induced fragile sites in lymphocytes of patients with breast cancer."
06/01/1993 - "The expression of aphidicolin-induced fragile sites in familial breast cancer patients."
06/01/1993 - "This indicates that the expression frequency of aphidicolin-induced fragile sites is not a suitable marker for assessing genetic susceptibility in familial breast cancer."
06/01/1993 - "The expression frequency of aphidicolin-induced fragile sites was examined in familial breast cancer patients to determine whether this parameter could be used as a marker of genetic susceptibility in at-risk individuals. "
11/01/1989 - "Frequency and distribution of aphidicolin-induced fragile sites (c-fra) on chromosomes of both peripheral blood lymphocytes (PBL) and bone marrow (BM) from 15 leukemia patients were studied in comparison with 22 PBL and six BM samples from healthy volunteers. "
12/15/1991 - "Aphidicolin was also effective in inhibiting megakaryocytic differentiation of other leukemia cell lines such as human erythroleukemia (HEL) and K562 cell lines induced with TPA, suggesting the close interplay of DNA replication and phenotypic expression in megakaryopoiesis."
03/01/2009 - "In this study, we used models of aphidicolin and nocodazole-synchronized HL-60 and NB4 leukemia cell lines to determine the kinetics of ERK activity during the progression of the cell cycle and to test the effects of commercially available inhibitors on G(2)/M progression of synchronized leukemia cells. "
06/01/1985 - "It is of interest that other inhibitors of S-phase DNA replication such as aphidicolin and hydroxyurea can also induce similar phenotypic changes in HL-60 and K562 leukemia cells. "
12/03/1993 - "We investigated the effect of aphidicolin, an inhibitor of DNA polymerase alpha and delta, on the induction of apoptosis by arabinosyl nucleosides in a human promyelocytic leukemia cell line, HL-60. "
|4.||DNA (Deoxyribonucleic Acid)
|7.||Caffeine (No Doz)